戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 oteinase-activated receptor-2 and cytochrome epoxygenase.
2 pase C (PLC) or cytochrome P450 arachidonate epoxygenase.
3 ed by PPOH and miconazole, inhibitors of CYP/epoxygenase.
4 tosolic phospholipase A2 and cytochrome P450 epoxygenase.
5 ls expressing high levels of cytochrome P450 epoxygenase.
6 - and enantioselective arachidonic acid (AA) epoxygenase.
7 mical selectivity of the kidney arachidonate epoxygenase.
8 bic oxygen/substrate binding site within the epoxygenase.
9 ) excretion, expresses cytochrome P450 (CYP)-epoxygenase.
10 rome P450 as the endogenous arachidonic acid epoxygenase.
11 nvolves phospholipase A2 and cytochrome P450 epoxygenases.
12 ADA) and N-arachidonoyl-serotonin (NA5HT) by epoxygenases.
13  small molecules produced by cytochrome P450 epoxygenases.
14 ted from arachidonic acid by cytochrome P450 epoxygenases.
15 athways of lipoxygenase, cyclooxygenase, and epoxygenase, 12-lipoxygenase of the lipoxygenase pathway
16  regio- and stereoselective arachidonic acid epoxygenase ((14S,15R)-epoxyeicosatrienoic acid, 99% of
17 he renal expression of cytochrome P450 (CYP) epoxygenase 2C23, which metabolizes arachidonic acid (AA
18          Endothelial cells lacking a Cyp2c44 epoxygenase, a PPARalpha target, show reduced proliferat
19                   Finally, inhibition of CYP-epoxygenase abolished iberiotoxin-sensitive and flow-sti
20 -modifying enzymes (desaturase, hydroxylase, epoxygenase, acetylenase, and conjugase) revealed severa
21 ired or inherited abnormalities in the renal epoxygenase activities and/or regulation and salt-sensit
22 f AA and 11,12-EET on ENaC by increasing CYP epoxygenase activity and decreasing sEH activity, respec
23                                              Epoxygenase activity decreased by 28%, 51%, and 26% in F
24 an essential role for Stat3 as a mediator of epoxygenase activity in breast cancer.
25 mal arachidonic acid metabolism, (2) reduced epoxygenase activity in F48 and F48/R6 rats is accompani
26 bronectin expression is under the control of epoxygenase activity in human and rat primary macrophage
27                                Inhibition of epoxygenase activity inhibited progesterone production s
28                                          CYP epoxygenase activity was analyzed by reverse-phase high-
29 m chloride (NaCl) for 7 days increased renal epoxygenase activity, both in the cortex and the medulla
30 nked to PLC and cytochrome P450 arachidonate epoxygenase activity.
31 fflux of 20-HETE, whereas 2% NaCl stimulated epoxygenase activity.
32 t this treatment had only a modest effect on epoxygenase activity.
33 sion of [(14)C]AA to HETEs without affecting epoxygenase activity.
34 ogical inhibition of brain P450 arachidonate epoxygenases also blocked morphine antinociception in mi
35 The enzyme consists of a terminal oxygenase (epoxygenase), an NADH-dependent reductase (reductase) an
36 antihypertensive role for the kidney Cyp2c44 epoxygenase and for its epoxyeicosatrienoic acid (EET) m
37 uces the activity of the kidney arachidonate epoxygenase and markedly increases the urinary excretion
38 0 2C23 matched that of the kidney microsomal epoxygenase and that excess dietary salt does not alter
39 pression and activity of the cytochrome P450 epoxygenases and hydroxylases.
40 al expression of the human CYP2J2 and CYP2C8 epoxygenases and mice with targeted disruption of Ephx2.
41 tial to mimic the activities of typical P450 epoxygenases and some capabilities of P450 hydroxylases.
42 P2J3 are abundant pulmonary arachidonic acid epoxygenases and that CYP2J products, the epoxyeicosatri
43 ocusing particularly on the CYP450 family of epoxygenases and the lipid mediators they produce.
44 evaluate in a systematic way the role of CYP epoxygenases and the metabolites they generate in cancer
45 etermined by the activity of cytochrome P450 epoxygenases and the soluble epoxide hydrolase (sEH), an
46 tabolites of cyclooxygenases, lipoxygenases, epoxygenases, and other sources.
47 idomic study revealed a dramatic increase in epoxygenase- and lipoxygenase-pathway-derived lipid medi
48        Here we show that the cytochrome P450 epoxygenase arachidonic acid metabolite 14,15-epoxyeicos
49                                          CYP epoxygenases are directly inhibited by H2O2, and this in
50 ), the catalytic products of cytochrome P450 epoxygenases, are PPARgamma ligands.
51 athways involving astrocytic cytochrome P450 epoxygenase, astrocytic cyclooxygenase-1 and smooth musc
52 rs of phospholipase A(2) and cytochrome P450 epoxygenase attenuated the sustained response, suggestin
53                                              Epoxygenases belong to the cytochrome P450 family.
54 nd rat intestine contain an arachidonic acid epoxygenase belonging to the CYP2J subfamily that is loc
55                            Inhibition of the epoxygenase blocked serum-induced endothelial cell proli
56                               Inhibiting CYP-epoxygenase but not cyclooxygenase- or CYP-omega-hydroxy
57 ufficient, catalytically active arachidonate epoxygenase can be constructed by fusing P450 2C11 to ma
58          We show here that lack of a Cyp2c44 epoxygenase causes dietary salt-sensitive hypertension,
59                                          The epoxygenase component contains a bridged diiron centre s
60                                          The epoxygenase component of this system has been purified w
61              These results indicate that the epoxygenase contains a bridged dinuclear iron centre sim
62                              Cytochrome P450 epoxygenases convert arachidonic acid into 4 epoxyeicosa
63 yclooxygenase (COX), lipoxygenase (LOX), and epoxygenase (CYP) pathways.
64 luded lipoxygenase (LO)- and cytochrome P450 epoxygenase (CYP)-derived eicosanoids.
65 at experimental elevation of cytochrome P450 epoxygenase (CYP)-derived epoxygenated fatty acids, epox
66                          The cytochrome P450 epoxygenase (CYP)-derived metabolites of arachidonic aci
67 EET) by the cytochrome P450 arachidonic acid epoxygenases (Cyp2c) represents a new and safe mechanism
68  that global deletion of the cytochrome P450 epoxygenase Cyp2c44, a major epoxyeicosatrienoic acid (E
69                              Cytochrome P450 epoxygenase Cyp2c44, a murine epoxyeicosatrienoic acid (
70                        Cytochrome P450 (CYP) epoxygenases CYP2C8 and CYP2J2 generate epoxyeicosatrien
71 a new human cytochrome P450 arachidonic acid epoxygenase (CYP2J2) and the corresponding rat homologue
72  described a new human P450 arachidonic acid epoxygenase (CYP2J2) and the corresponding rat homologue
73 12-EET, or overexpression of the endothelial epoxygenase, CYP2J2, increased tissue plasminogen activa
74 ed gene deletion of the major rat macrophage epoxygenase Cyp2j4 (ortholog of human CYP2J2) resulted i
75 ken together, these results identify the rat epoxygenase Cyp2j4 as a determinant of a profibrotic mac
76  increased expression of the cytochrome-P450-epoxygenase CYP2J6 and increased concentrations of its l
77  phospholipase A2 (PLA2) and cytochrome P450 epoxygenases (CYP450s) were able to block the laminar fl
78 YP2J2 in the rat, as well as the role of CYP-epoxygenase-dependent metabolism of arachidonic acid in
79                            Thus, these cP450 epoxygenase-dependent metabolites are a novel class of e
80 esent study describes a novel group of cP450 epoxygenase-dependent metabolites of arachidonic acid, t
81 ibition of ENaC, an effect mediated by a CYP-epoxygenase-dependent pathway.
82            Cyclooxygenase, lipoxygenase, and epoxygenase derived oxylipins, especially eicosanoids, p
83 cyclooxygenase- or cytochrome P450-dependent epoxygenase-derived AA metabolites, are specifically req
84 xygenase inhibitor, directly implicating CYP epoxygenase-derived EETs with the observed anti-inflamma
85 gh the cAMP-PKA pathway and suggest that CYP epoxygenase-derived eicosanoids may play important roles
86 osatrienoic acids (EETs) are cytochrome P450-epoxygenase-derived metabolites of arachidonic acid that
87 pathways; (b) provide evidence for a Cyp2c44 epoxygenase, EET-mediated mechanism of ENaC regulation i
88  Moreover, transfection of a bacterial 14,15-epoxygenase established intracellular endogenous 14,15-E
89  is a keratinocyte-specific arachidonic acid epoxygenase expressed in the granular cell layer of mous
90 alpha down-regulates endothelial cell CYP2C9 epoxygenase expression and blunts proliferation and tubu
91 a demonstrate that increased endothelial CYP epoxygenase expression attenuates afferent arteriolar co
92  (EETs), hepatic EET biosynthesis, and Cyp2c epoxygenase expression.
93 an active regio- and stereoselective 14S,15R-epoxygenase (F87V BM-3).
94 cells) expressing a mutant bacterial P450 AA epoxygenase, F87V BM3, which was genetically engineered
95 al infusion of inhibitors of cytochrome P450 epoxygenases (fluconazole) and NO synthase (N(G)-monomet
96 g results showed that protein expressions of epoxygenases from cytochrome P450 (CYP)2B, 2C and 2J sub
97  lipid mediators produced by cytochrome P450 epoxygenases from omega-3 fatty acid docosahexaenoic aci
98             We conclude that endothelial CYP epoxygenase function contributes to the regulation of bl
99 e of the PPARalpha receptor and of its Cyp2c epoxygenase gene target in tumorigenesis, we treated mic
100 , characterize the contribution of its Cyp2c epoxygenases gene target to these responses, and suggest
101                        Cytochrome P450 (CYP) epoxygenases generate bioactive lipid epoxides which can
102 mega-hydroxylases and Cyp2c arachidonic acid epoxygenase genes.
103 om arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiova
104 ide evidence for this potentiation using the epoxygenase human CYP2J2.
105 P450 family of enzymes, is the most abundant epoxygenase in the heart and has multifunctional propert
106  acid omega-hydroxylase and arachidonic acid epoxygenase in the noninfected cells, (b) the CYP 4A3-de
107  P-450 2C23 is the major 2C arachidonic acid epoxygenase in the rat kidney and the renal P-450 isofor
108 ET) was the major product metabolized by CYP epoxygenases in rat corpora cavernosa.
109 s support a physiological role for 14,15-EET epoxygenases in regulating epidermal cornification, and
110 ference in the levels of the CYP2E and CYP2C epoxygenases in SHR and WKY kidneys.
111 ans, we establish the relative expression of epoxygenases in these cells.
112 ienoic acids, vasodilator metabolites of CYP/epoxygenase, in arterioles incubated with 17beta-E2, a r
113 r results suggest that EETs, produced by CYP epoxygenases, in penile endothelial cells serve as vasod
114 s, products of the kidney P-450 arachidonate epoxygenase, inhibit distal nephron Na(+) reabsorption.
115 y added EETs rescued cell proliferation from epoxygenase inhibition.
116 hannel activity, even in the presence of CYP-epoxygenase inhibition.
117 d both were reduced to similar levels by CYP epoxygenase inhibition.
118 ic features that were ameliorated by the CYP epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propynylox
119 ith cirrhosis were treated with the specific epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propynylox
120            Perfusion with the selective P450 epoxygenase inhibitor N-methylsulphonyl-6-(2-proparglylo
121                                          The epoxygenase inhibitor SKF525A (epoxI) given at 24 h sele
122 e dilation was unaffected by cytochrome-P450 epoxygenase inhibitor sulfaphenazole.
123 ooxygenase inhibitor) and sulfaphenazole (an epoxygenase inhibitor).
124 y a putative EET receptor antagonist and CYP epoxygenase inhibitor, directly implicating CYP epoxygen
125 A), the 5-lipoxygenase inhibitor, AA861, the epoxygenase inhibitor, miconazole, and the cyclooxygenas
126                                         Both epoxygenase inhibitors completely prevented the arachido
127 oxygenase, lipoxygenase, or cytochrome P-450 epoxygenase inhibitors did not reverse the inhibition ca
128            In contrast, the cytochrome P-450 epoxygenase inhibitors, SKF525A and metyrapone, substant
129 cts were inhibited by preincubation with CYP epoxygenase inhibitors.
130 xygenases, but not cytochrome P450-dependent epoxygenases inhibits Ang II- or AA-induced RGS2 mRNA ex
131  angiogenesis and growth, and (c) the CYP2C9 epoxygenase is expressed in the vasculature of human tum
132 ETs or compared the effects of different CYP epoxygenase isoforms in the ischemic heart.
133 om arachidonate by inducible cytochrome P450 epoxygenase isoforms, and tissue EET profiles may vary w
134 y human recombinant CYP 2C9 and 2J2, 2 major epoxygenase isozymes expressed in human coronary arterio
135                                      CYP2C44 epoxygenase knockdown blunted the sodium transport effec
136  as ENaC inhibitors, and (d) suggest a CYP2C epoxygenase-mediated pathway for the regulation of dista
137   Our findings indicate that a neuronal P450 epoxygenase mediates the pain-relieving properties of mo
138 en endocannabinoid and cytochrome P450 (CYP) epoxygenase metabolic pathways.
139                         Docosahexaenoic acid epoxygenase metabolite 19,20-dihydroxy-4Z,7Z,10Z,13Z,16Z
140  study demonstrates that a P450 arachidonate epoxygenase metabolite can activate cleavage of heparin-
141 -epoxyeicosatrienoic acid, a cytochrome P450 epoxygenase metabolite of arachidonic acid, may be a com
142 eases in the plasma levels of pro-angiogenic epoxygenase metabolites (EETs), hepatic EET biosynthesis
143         The cytochrome P450 arachidonic acid epoxygenase metabolites are resolved, without the need f
144 ze a mechanistic commonality between EGF and epoxygenase metabolites as ENaC inhibitors, and (d) sugg
145 ated biological activities attributed to the epoxygenase metabolites in cell proliferation, angiogene
146 noic acids (EETs), the cytochrome P450 (CYP) epoxygenase metabolites of arachidonic acid (AA), are po
147                                              Epoxygenase metabolites of arachidonic acid are produced
148 satrienoic acids (EETs), the cytochrome P450 epoxygenase metabolites of arachidonic acid, are potent
149         The cytochrome P450 arachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (
150               Roles for the arachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (
151 harmacological inhibition of cytochrome P450 epoxygenases opened the myocardial mPTP in human heart m
152 denovirus particles expressing a 14S,15R-EET epoxygenase (P450 BM3v).
153 t unequivocal evidence for a role for the AA epoxygenase pathway and endogenous EET synthesis in EGF-
154 ata demonstrate that potentiation of the CYP epoxygenase pathway by either increased endothelial EET
155 s of ion channels, little is known about the epoxygenase pathway in labor.
156                                              Epoxygenase pathway metabolites are established regulato
157 Ts are produced by the cytochrome P450 (CYP) epoxygenase pathway of arachidonic acid (AA) metabolism
158                              Blockade of the epoxygenase pathway was ineffective, whereas blocking ei
159 ion, high dietary K stimulates the renal CYP-epoxygenase pathway, which plays an important role in ac
160 ing the central roles of the cytochrome P450 epoxygenase pathway.
161 rough cyclooxygenase, lipoxygenase, or P-450 epoxygenase pathways can generate a variety of eicosanoi
162 es for the cyclo-oxygenase, lipoxygenase and epoxygenase pathways, but specific inhibitors of these p
163  which are products of cytochrome P450 (CYP) epoxygenases, possess vasodilatory, antiinflammatory, an
164 cosatetraenoic; however, the cytochrome P450 epoxygenase product 5,6-epoxyeicosatrienoic acid is prim
165 onic acid (AA) metabolism and synthesized AA epoxygenase products (+/-)-8,9-, (+/-)-11,12-, and (+/-)
166  cells represents not only a novel action of epoxygenase products from EFAs, but also a potentially s
167                                          The epoxygenase products, the epoxyeicosatrienoic acids, are
168                 Furthermore, cytochrome P450 epoxygenase promotes cell survival both by production of
169  lipid mediators produced by cytochrome P450 epoxygenases, regulate inflammation, angiogenesis, and v
170 ha points to a role for the receptor and its epoxygenase regulatory target in the pathophysiology of
171 olism of arachidonic acid by the mouse renal epoxygenase(s).
172 ut not of cyclooxygenase or cytochrome P-450 epoxygenase, significantly attenuated the vasodilations
173 s into the proposed active-site model of the epoxygenase suggested that Ala91 and Ala185 were respons
174 cids (EETs) are products of cytochrome P-450 epoxygenase that possess important vasodilating and anti
175 s indicate that CYP3A4 is a highly active AA epoxygenase that promotes Stat3-mediated breast cancer c
176 (EETs) are products of cytochrome P450 (CYP) epoxygenases that have vasodilatory and anti-inflammator
177 acids (EETs) are products of cytochrome P450 epoxygenases that have vasodilatory properties similar t
178  cytochrome P450 (CYP) 2J2 is one of the CYP epoxygenases that metabolize arachidonic acid to produce
179 ere blocked by inhibitors of cytochrome P450 epoxygenase, the synthetic enzyme for epoxyeicosatrienoi
180  metabolism of NADA, NA5HT and other eCBs by epoxygenases to form the corresponding epoxides.
181 arachidonate is oxidized by cytochrome P-450 epoxygenases to four epoxyeicosatrienoic acids (EETs): 1
182 al expression of the human CYP2J2 and CYP2C8 epoxygenases to increase endothelial EET biosynthesis.
183 ne line of mice harboring a cardiac-specific epoxygenase transgene developed head swelling and rapid
184 ing a human cytochrome P450 arachidonic acid epoxygenase was isolated from a human liver cDNA library
185                        Brain cytochrome P450 epoxygenases were recently shown to play an essential ro

 
Page Top